Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
SHANGHAI, May 16, 2025 /PRNewswire/ -- Nuance Pharma ("Nuance") today announces its top-line Phase 3 ENHANCE-CHINA (NCT05743075) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"). The ENHANCE-CHINA trial has successfully met its primary endpoint, as well as secondary endpoints demonstrating improvements in lung function.
The investigational study drug, ensifentrine is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3; PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.
Highlights
- Study population (n = 526 randomized):
Subject demographics and disease characteristics were well balanced between treatment groups
Approximately 46% of subjects received background COPD therapy, either a long-acting muscarinic antagonist ("LAMA") or a long-acting beta-agonist ("LABA"). Additionally, approximately 38% of all subjects received inhaled corticosteroids ("ICS") with concomitant LABA.
- Primary endpoint met (FEV1 AUC 0-12hr):
Placebo corrected, change from baseline in average FEV1 area under the curve 0-12 hours post dose at week 12 was 110 mL (p<0.0001) for ensifentrine
Statistically significant and clinically meaningful improvements with ensifentrine demonstrated across key subgroups including age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV1 reversibility
- Secondary endpoints of lung function:
Placebo corrected, increase in peak FEV1 of 174 mL (p<0.0001) at week 12
Placebo corrected, increase in morning trough FEV1 of 36 ml (p=0.0533) and evening trough FEV1 of 65 ml (p=0.0038) at week 12, confirming twice daily dosing regimen.
Placebo corrected, increase in average FEV1 of 162 ml (p<0.0001) 0-4 hours post dose and 77 mL (p=0.0003) 6-12 hours post dose at week 12
- COPD symptoms and quality of life (QoL):
Clinically meaningful improvements in dyspnea as measured by Transition Dyspnea Index (TDI) in the ensifentrine group were observed at all weeks (6, 12 and 24) with a statistically significant improvement of 0.8 unit compared to placebo at week 24.
Quality of Life (QoL) as measured by St George's Respiratory Questionnaire (SGRQ) Total Score in the ensifentrine group improved from baseline to greater than the MCID of -4 units with a significant improvement of -2.9 units compared to placebo at week 24.
Daily symptoms as measured by Evaluating Respiratory Symptoms (E-RS) Total Score in ensifentrine group showed improvement from baseline as early as 6 weeks and continued improvement at 12 and 24 weeks, numerically exceeding placebo at each measurement.
- Exacerbation rate reduced
Subjects receiving ensifentrine demonstrated a 28% reduction in the rate of moderate/severe COPD exacerbations over 24 weeks compared to those receiving placebo (RR = 0.72, 95% CI: (0.43, 1.22))
Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 25% (HR = 0.75, 95% CI: (0.44, 1.28))
- Favorable safety profile:
Ensifentrine was well-tolerated with treatment related AE incidence similar to placebo
Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, said:"We are very pleased by the successful outcome of our Phase 3 ENHANCE-CHINA study, bringining us another step closer to providing a much needed novel therapy for COPD patients in China. These promising results demonstrate ensifentrine's strength as a first-in-class bronchodilator and non-steroidal anti-inflammatory therapy for COPD, as an advance to existing treatment options. We plan to submit a New Drug Application to the China NMPA in the second half of 2025. We would like to thank all the patients and investigators for their participation in the ENHANCE-CHINA program. "
Charlie Chen, Chief Operating Officer of Nuance Pharma added:"The totality of ENHANCE data including improvements in lung function, symptoms, quality of life measure and reduction in exacerbations, coupled with favorable safety profile, support our belief that ensifentrine will change the treatment paradigm for COPD. Following our ongoing early access programs in Hainan BoAo and Greater Bay Area, as well as regulatory approval in Macau, we look forward to bringing this medicine to patients in Greater China."
David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said:"we look forward to Nuance Pharma's continued progress and having Ohtuvayre® available for the millions of symptomatic patients needing additional treatment."
Nuance Pharma plans to release additional information from ENHANCE-CHINA at upcoming scientific conferences.
In Feb 2025, the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients. In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China's Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE-CHINA, the phase 3 clinical trial of Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD.
In June 2024, Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announced the US Food and Drug Administration ("FDA") approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients.
In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize Ohtuvayre™ (ensifentrine) in Greater China (mainland China, Hong Kong, Macau and Taiwan).
About Ohtuvayre™ (ensifentrine)Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre™ in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD maintenance treatment. Ohtuvayre™ met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.
About the ENHANCE-CHINA programThe randomized, double-blind, placebo-controlled study evaluate the efficacy and safety of nebulized ensifentrine as monotherapy and added onto a single bronchodilator, either a LAMA or a LABA, compared to placebo, and subjects may receive ICS.
Patient Population: 526 moderate to severe, symptomatic, COPD patients at 46 sites in China.
Dose/Duration: subjects were randomized to receive a 3mg nebulized dose of ensifentrine or nebulized placebo twice daily for 24 weeks
Primary Endpoint: Improvement in lung function with ensifentrine as measured by average FEV1 AUC 0-12 hours post dose at week 12.
Secondary Endpoints: lung function endpoints including peak and morning trough FEV1, COPD symptoms and health related quality of life through 24 weeks via SGRQ and E-RS, and exacerbation at 24 weeks, and others
Safety: Assessed over 24 weeks
Further information about ENHANCE-CHINA program can be found at www.clinicaltrials.gov (NCT05743075)
About Verona PharmaVerona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ohtuvayre™ (ensifentrine) has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
About Nuance PharmaNuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com.
Forward-looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
View original content:https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ensifentrine-meets-primary-endpoint-in-phase-3-enhance-china-trial-for-copd-302457563.html
SOURCE Nuance Pharma Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Dental Remains Reveal Odd Mating Habits of Early Humans
Dental remains dating back 300,000 years, which were discovered at a well-known Chinese archaeological site, have revealed surprising information about human breeding practices, according to a new study published in the Journal of Human Evolution. What did the study find? Researchers say the groundbreaking discovery, which was the result of a decade-long international collaboration between Beijing's Institute of Vertebrate Paleontology and Paleoanthropology and Spain's Centro Nacional de Investigación sobre la Evolución Humana, represents something which has 'never [been] seen before' on the fossil record. The teeth combine archaic features often found in Homo erectus, like strong molar and premolar roots which are characteristic of Middle Pleistocene hominins, with more advanced traits present in Homo sapiens, like smooth buccal surfaces and occlusal outlines. This suggests that human evolution in Asia was much more complicated than previously thought, with humans interbreeding with Homo erectus. What Are the Experts Saying? "It's a mosaic of primitive and derived traits never seen before – almost as if the evolutionary clock were ticking at different speeds in different parts of the body," explained María Martinón-Torres, the study's co-author. The evidence suggests that modern Homo sapiens were in Asia up to 300,000 years ago, which is much earlier than previously thought. Paleobiologist José María Bermúdez de Castro explained that "the Hualongdong discovery reminds us that human evolution was neither linear nor uniform, and that Asia hosted multiple evolutionary experiments with unique anatomical outcomes." The dental remains share many similarities with the teeth of Late Pleistocene hominins, indicating that modern human traits began emerging in Asia long before Homo erectus spread across the globe. Scientists will next conduct additional experimentation to determine the precise evolutionary position and identity of the species to which the teeth Remains Reveal Odd Mating Habits of Early Humans first appeared on Men's Journal on Aug 14, 2025 Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
The US May Have Already Lost the AI Race to China Due to a Key Weakness
You might have heard of an "AI race" heating up between the US and China, a bitter rivalry between two global adversaries that could shape the direction of world history. At least, that's how some in the US feel. While China has repeatedly tried to establish a geopolitical friendship with the richest nation in the world, officials and pundits in the US have doubled down, reframing artificial intelligence as the 21st century's nuclear bomb. In the meantime, China may have gotten a massive lead — by actively investing in its power grid, while the United States' is quickly running out of capacity to power immensely power-hungry AI models. As Fortune reports, Americans who've had a look at China's technological development firsthand found that the two country's aren't even in the same league, given China's next-level power grid. "Energy is considered a solved problem," wrote Rui Ma, editor of the US publication Tech Buzz China. "Everywhere we went, people treated energy availability as a given," she continued. "This is a stark contrast to the US, where AI growth is increasingly tied to debates over data center power consumption and grid limitations." AI is a notoriously energy-intensive technology. The data centers powering large language models like ChatGPT are immense labyrinths of computer chips, which suck down resources like power and water in order to keep up with demand. As Fortune notes, this effectively makes electricity the key bottleneck for expanding AI infrastructure. That's caused some critical shortages in the US. Short on energy and hopped up on fantasies of an arms race, American companies are resorting to all kinds of bizarre strategies to get their juice. Elon Musk's xAI, for example, is running 35 portable methane gas generators in the parking lot of one of its main datacenters in Memphis, encircling nearby communities in a cloud of noxious smog. China has no such problems. In 2024, China was responsible for nearly 65 percent of the world's renewable energy construction, installing so many solar panels and wind turbines that it caused the country's CO2 emissions to drop for the first time — despite record-high demands for energy. Whether or not the US can catch up remains to be seen. President Donald Trump previously made an off-the-cuff remark about attaching coal power plants to data centers directly. It's an unfortunate conundrum in an age when energy demand in the US has never been higher. In the meantime, China keeps chugging along, seemingly unperturbed by any energy bottlenecks — and the Trump administration's posturing. More on AI: AI Datacenters Are Raising Nearby Residents' Electric Bills Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
Local residents develop ranches of unusual species to revive coral reefs: 'We've raised thousands'
Local residents develop ranches of unusual species to revive coral reefs: 'We've raised thousands' It might look like a pickle or simply a brownish lump, but don't let the unassuming appearance of a sea cucumber fool you. For the coastal ecosystems of the Philippines, the cucumbers are critical for marine life, local economies, and food supplies. But overfishing in the 1970s and '80s depleted their populations, throwing entire ecosystems out of whack well into the 2000s. To address the problem, an unlikely fleet of heroes has arisen with the development of sea cucumber ranches, the BBC reported. These ranches serve as nurseries and breeding grounds for the marine species from larval through mature ages. For perspective, the daily catch per person in the small town of Bolinao was up to 220 pounds a day in the 1980s. By 2002, that had plummeted to fewer than 6 pounds. "When I was a child, I used to see loads of them, but now that I'm older, they've become so little," said Aweng Caasi, a 61-year-old widow and one of the key ranchers and guardians of the sea cucumbers in Bolinao. "We want to restore them so they can multiply." The cucumbers are eaten for food and used in medicine, but they provide even more value in their natural environment. They're often nicknamed the janitors of the sea, cleaning up the seafloor by munching on bacteria and decaying organic matter. This recycles beneficial nutrients into the environment, making waters more hospitable to a variety of fish species. They were even found to be linked to lower disease rates among corals, according to a study published in the journal Nature Communications. Humans benefit tremendously from a healthier marine environment, too. In Bolinao, the reef provides protection from storms, fish to sell and eat, and a major draw for tourists. "This is a big help for us fisherfolk," Gemma Candelario told BBC. Gemma and Marivic Carolino raise mangroves near Bolinao, and they began monitoring and guarding sea cucumbers in their area in 2022. Do you think America does a good job of protecting its natural beauty? Definitely Only in some areas No way I'm not sure Click your choice to see results and speak your mind. "The sea cucumbers would eat waste [cleaning the ecosystem] so that's why more fish would appear. Some fish would lay eggs in our mangroves and other animals would appear such as crabs and shrimp." The program is mostly managed by women and children, who raise the cucumbers in hatchery tanks at the University of the Philippines Marine Science Institute (UPMSI) before transferring them to the ranches. There, they guard their protected areas against poachers. Aweng Caasi, for example, regularly spends hours at a time sitting in a wooden hut over Bolinao's waters. The program has been tremendously successful; in its first 19 months, the local sea cucumber population grew more than 13 times its original size, from 400 individuals in 2007 to over 5,500 in 2009. "It makes me happy to see the ones I've cared for grow bigger, and to see more of them," Candelario said. "We've raised thousands and we see them clearly during the monitoring period. I can't help but be glad to see how many they've grown to become." Following its remarkable success, the provincial government approved an ordinance in January to officially declare several of the dedicated areas as protected sea cucumber reserves. The law also prohibited harvesting or trading sea cucumbers below a certain weight to maintain mature reproductive populations. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
